Talquetamab-Induced Dysgeusia Successfully Treated With Photobiomodulation Therapy.

Multiple myeloma is a malignancy characterized by clonal proliferation of plasma cells in the bone marrow. The treatment of patients with relapsed or refractory multiple myeloma remains a challenge. Talquetamab is a recently approved drug, a first-in-class GPRC5D-targeting T-cell redirecting bispecific antibody, for treatment of patients with triple-class exposed relapsed/refractory multiple myeloma.